CAMBRIDGE, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday,
November 11, 2005 at 9:00 a.m. EST. During the call, the Company will review
results from the Phase Ib study of its investigational oral hepatitis C
protease inhibitor, VX-950, that will be presented while attending the 56th
American Association for the Study of Liver Diseases (AASLD) Annual Meeting.
The meeting is being held in San Francisco, CA from November 11-15, 2005.
The webcast will be available to all interested parties through Vertex's
website, http://www.vrtx.com, and will be archived on the Company's website
until November 25, 2005. To access the webcast, go to the investor center and
select 'conference calls.' To ensure a timely connection, it is recommended
that users register at least 15 minutes prior to the scheduled webcast.
Vertex is also providing a podcast MP3 file available for download on the
Vertex website, http://www.vrtx.com, until November 25, 2005.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes
the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Contact:
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com
Company News On-Call:
http://www.prnewswire.com/comp/938395.html
CONTACT:
Lora Pike, Manager, Investor Relations of
Vertex Pharmaceuticals Incorporated, +1-617-444-6755
|
